Sumitomo Dainippon Pharma acquires Tolero Pharma and with it six compounds and alvocidib a treatment proposed for AML.

Sumitomo Dainippon Pharma Co., Ltd. announced that it has completed the acquisition of Tolero Pharmaceuticals, Inc. , as of January 25, 2017.Through this transaction, Sumitomo Dainippon Pharma has acquired six compounds, including a cyclin-dependent kinase 9 (CDK9) inhibitor alvocidib, which is under clinical development by Tolero for the treatment of hematologic malignancies, and has strengthened its development pipeline in oncology, one of its focus therapeutic areas. Alvocidib is currently being investigated in a Phase II study for biomarker-positive patients with acute myeloid leukemia (AML) in the U.S., and a New Drug Application is planned for submission to the FDA in fiscal 2018 at the earliest.